Article Details
Retrieved on: 2024-10-02 19:12:27
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
BridgeBio receives FDA's regenerative medicine advanced therapy (RMAT) designation for BBP-812 Canavan disease gene therapy program. News release ...
Article found on: www.cgtlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here